BTAI - CIK 0001720893
BioXcel Therapeutics, Inc. (BTAI) reported net income of -$69.90M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$69.90M | -17.3% |
| FY 2024 | -$59.60M | +66.7% |
| FY 2023 | -$179.05M | -8.0% |
| FY 2022 | -$165.76M | -55.0% |
| FY 2021 | -$106.93M | -30.1% |
| FY 2020 | -$82.17M | -149.2% |
| FY 2019 | -$32.97M | -71.1% |
| FY 2018 | -$19.27M | -324.5% |
| FY 2017 |
BioXcel Therapeutics, Inc. (BTAI) reported net income of -$69.90M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, BioXcel Therapeutics, Inc.'s net income declined from -$4.54M to -$69.90M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$4.54M |
| - |